Welcome to our dedicated page for RETINALGENIX TECHNOLOGIES news (Ticker: RTGN), a resource for investors and traders seeking the latest updates and insights on RETINALGENIX TECHNOLOGIES stock.
RetinalGenix Technologies Inc (RTGN) specializes in advanced retinal imaging systems designed to transform ocular health screening through noninvasive technology. This page serves as the definitive source for official announcements, financial disclosures, and progress updates related to their high-resolution imaging platforms and genetic research initiatives.
Investors and healthcare professionals will find timely updates on regulatory milestones, clinical study results, and strategic partnerships. Our curated collection includes earnings reports, product development announcements, and analyses of RTGN's role in telemedicine-enabled eye care solutions.
Key content areas cover device approvals, research collaborations, financial performance, and technology enhancements. All materials are sourced from verified corporate communications to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page for streamlined access to RetinalGenix's latest developments in medical imaging innovation and their expanding impact on accessible eye care solutions across clinical settings.
RetinalGeniX Technologies (RTGN) will present at the Emerging Growth Conference on October 26, 2022, at 1:00 PM Eastern. The 30-minute presentation will be led by Jerry Katzman, the company's CEO, highlighting its mission to prevent blindness through innovative retinal screening and home monitoring. Additionally, the company aims to diagnose systemic diseases, including heart disease and Alzheimer’s, via genetic mapping. Attendees can register for live participation or access an archived webcast post-event.
RetinalGenix Technologies (OTCQB:RTGN) announced the appointment of Dr. Vinay Mehindru to its Board of Directors, aimed at enhancing initiatives for population health management and supporting the company's planned upgrade from OTCBQB to NASDAQ.
Dr. Mehindru brings over 25 years of healthcare expertise, holding leadership roles that integrate clinical and financial operations. His experience includes serving as Chief Medical Officer and building extensive physician networks.
RetinalGenix anticipates his contributions will improve the efficiency and effectiveness of its health screening technologies.
RetinalGeniX Technologies has acquired DNA/GPS Inc., a pharmacogenetics firm, enhancing its capabilities in retinal imaging and genetic mapping. This acquisition aims to revolutionize the diagnosis of systemic diseases like heart disease and Alzheimer’s by allowing healthcare providers to conduct tests at primary care centers, significantly reducing costs compared to traditional methods. The platform is expected to enable early detection and interventions, focusing on patients with genetic predispositions to various diseases, with industry expertise led by Dr. Larry Perich.
FAQ
What is the current stock price of RETINALGENIX TECHNOLOGIES (RTGN)?
What is the market cap of RETINALGENIX TECHNOLOGIES (RTGN)?
